Regeneron’s stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after analysts had just placed a high probability of a positive result.
www.marketwatch.com
#Regeneron #dashes #Wall #Streets #hopes #COPD #treatment #trial #suffers #failure
Regeneron dashes Wall Street’s hopes as COPD treatment trial suffers a failure
